We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
-8.04%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$255M
AUM Growth
-$24.4M
Cap. Flow
+$13.3M
Cap. Flow %
5.21%
Top 10 Hldgs %
71.55%
Holding
30
New
5
Increased
10
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$13.3M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.33M
3
CTNM
Contineum Therapeutics
CTNM
+$7.85M
4
MRUS
Merus
MRUS
+$4.97M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$4.18M

Top Sells

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$15.8M
2
NMRA icon
Neumora Therapeutics
NMRA
+$5.72M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.82M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.63M
5
COGT icon
Cogent Biosciences
COGT
+$2.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
1
Disc Medicine
IRON
$2.88B
$32.3M 12.65%
509,406
-1,635
-0.3% -$94.6K
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$27.4M 10.73%
198,977
-1,308
-0.7% -$172K
MLTX icon
3
MoonLake Immunotherapeutics
MLTX
$1.66B
$18.7M 7.34%
346,111
+47,137
+16% +$2.41M
CGON icon
4
CG Oncology
CGON
$6.47B
$17M 6.66%
593,262
+73,143
+14% +$2.5M
PCVX icon
5
Vaxcyte
PCVX
$8.05B
$16.7M 6.55%
204,285
-702
-0.3% -$69.7K
CYTK icon
6
Cytokinetics
CYTK
$11.1B
$16.4M 6.42%
348,364
+17,081
+5% +$887K
CRGX
7
DELISTED
CARGO Therapeutics
CRGX
$14.5M 5.69%
1,007,677
+5,216
+0.5% +$94.7K
CELC icon
8
Celcuity
CELC
$4.05B
$13.9M 5.45%
1,063,783
+117,448
+12% +$1.66M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.85B
$13.1M 5.12%
988,528
+486,550
+97% +$8.33M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.35B
$12.6M 4.95%
+322,470
New +$13.3M
ARGX icon
11
argenx
ARGX
$56.2B
$12.1M 4.76%
19,754
-2,357
-11% -$1.38M
COGT icon
12
Cogent Biosciences
COGT
$6.92B
$11.7M 4.58%
1,498,425
-214,474
-13% -$2.14M
MRUS
13
DELISTED
Merus
MRUS
$9.87M 3.86%
234,637
+103,397
+79% +$4.97M
CTNM
14
Contineum Therapeutics
CTNM
$526M
$8.39M 3.29%
573,022
+495,725
+641% +$7.85M
ABVX
15
Abivax
ABVX
$11.1B
$4.78M 1.87%
653,071
+5,052
+0.8% +$46.5K
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$4.71M 1.85%
556,489
– –
INZY
17
DELISTED
Inozyme Pharma
INZY
$3.81M 1.49%
1,374,582
+5,772
+0.4% +$22K
IRWD icon
18
Ironwood Pharmaceuticals
IRWD
$645M
$3.61M 1.41%
814,533
-305,876
-27% -$1.24M
AMLX icon
19
Amylyx Pharmaceuticals
AMLX
$2.06B
$3.36M 1.32%
+889,073
New +$4.18M
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.02M 1.18%
59,125
-50,442
-46% -$2.82M
SLN
21
Silence Therapeutics
SLN
$561M
$2.72M 1.06%
395,024
-86,103
-18% -$1.11M
NAMS icon
22
NewAmsterdam Pharma
NAMS
$3.55B
$2.57M 1.01%
+100,000
New +$2.12M
OCUL icon
23
Ocular Therapeutix
OCUL
$1.9B
$1.64M 0.64%
+191,456
New +$1.87M
MBX
24
MBX Biosciences
MBX
$2.92B
$332K 0.13%
+18,000
New +$384K
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$11.8B
– –
-37,432
Closed -$2.63M
1
2

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Saturn V Capital Management held 30 positions worth $255M, down 8.7% from $280M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Saturn V Capital Management deployed $13.3M of net new capital in Q4 2024, opening 5 new positions and adding to 10 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 322,470 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Crinetics Pharmaceuticals, an estimated $2.82M trimmed.

  • Saturn V Capital Management's largest Q4 2024 buy was Xenon Pharmaceuticals: 322,470 shares worth $12.6M.
  • Saturn V Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $8.33M increase.
  • Saturn V Capital Management's biggest Q4 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $2.82M.
  • Saturn V Capital Management fully exited Phathom Pharmaceuticals in Q4 2024, selling an estimated $15.8M.
  • Saturn V Capital Management's ten largest holdings make up 72% of its $255M portfolio in Q4 2024.
  • Saturn V Capital Management opened 5 new positions and closed 6 in Q4 2024.
  • Saturn V Capital Management's portfolio value fell 8.7% quarter-over-quarter to $255M.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.